UPDATE : Wednesday, August 21, 2019
상단여백
Lilly’s anticancer combo drug nears getting insurance benefit by Kim Yun-mi 2019-08-07 15:44
Over 5,700 patients received Allergan’s breast implants linked to rare cancer by Song Soo-youn 2019-08-07 15:43
[Reporter’s Notebook] SillaJen should be ashamed of itself by Jeong Sae-im 2019-08-07 13:59
Lilly reports improved survival for Verzenio in P3 trial by Lee Han-soo 2019-08-07 12:06
ISU Abxis to unveil p1 results for anticancer treatment in Europe by Lee Han-soo 2019-08-07 12:03
라인
Crystal Genomics signs accord with CRO firm by Lee Han-soo 2019-08-06 17:20
Myongji Hospital opens sports medicine center by Lee Han-soo 2019-08-06 16:54
Japanese firms fear boycott may hurt prescription drug sales by Kim Yun-mi 2019-08-06 15:44
Sillajen cites salvation therapy as reason for trial suspension advice by Lee Han-soo 2019-08-06 15:43
HLB to seek pre-NDA meeting with FDA for rivoceranib by Jeong Sae-im 2019-08-06 15:43
라인
Market value of biopharmaceuticals drops ₩10 trillion on 'Black Monday' by Lee Han-soo 2019-08-06 13:50
Roche, MSD, AstraZeneca: top 3 risers on NASDAQ biotech by Kim Yun-mi 2019-08-06 11:29
South Koreans learn to thank life by experiencing death by Lee Han-soo 2019-08-06 06:00
Pharmicell submits investigational new drug application for prostate cancer treatment by Lee Han-soo 2019-08-05 17:59
Crystal Genomics confirms efficacy of inflammatory bowel disease treatment by Lee Han-soo 2019-08-05 17:02
라인
Sillajen’s trouble heralds fall of one of most prominent biotech firms by Lee Han-soo 2019-08-05 16:55
Boycott of Japanese drug intensifies as Seoul-Tokyo relations worsen by Lee Han-soo 2019-08-05 16:01
Amgen’s lipid-lowering Repatha beats Sanofi’s Praluent in Q2 sales by Kim Yun-mi 2019-08-05 15:37
SillaJen remains confident about Pexa-Vec’s value, despite trial failure by Jeong Sae-im 2019-08-05 14:49
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension by Jeong Sae-im 2019-08-05 11:26
여백
여백
여백
Back to Top